The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section.
* Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases?
* Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section.
Participants will:
* Be given 50mcg or 100mcg of carbetocin during cesarian section
* Asked to report cardiac symptoms
* Be assessed for ECG changes and blood loss using standard of practice monitoring
* Have a troponin I blood test completed after delivery

开始日期2025-08-01

申办/合作机构

Queen's University

CTRI/2025/04/084848

/ Not yet recruitingN/AIIT

A comparative study of hemodynamic effects of Oxytocin and Carbetocin in women undergoing lower segment cesarean section under spinal anaesthesia - NIL

开始日期2025-05-01

申办/合作机构

Banaras Hindu University

CTRI/2025/04/084329

/ Not yet recruitingN/AIIT

Hemodynamic effects of Oxytocin and Carbetocin during elective Cesarean Section under spinal anesthesia in Preeclamptic patients receiving Magnesium sulfate: A Randomized double-blind controlled study.

开始日期2025-04-15

申办/合作机构-

100 项与卡贝缩宫素相关的临床结果

登录后查看更多信息

100 项与卡贝缩宫素相关的转化医学

登录后查看更多信息

100 项与卡贝缩宫素相关的专利（医药）

登录后查看更多信息

498

项与卡贝缩宫素相关的文献（医药）

2025-12-31·HYPERTENSION IN PREGNANCY

Statement of Retraction: Carbetocin versus oxytocin for prevention of postpartum hemorrhage in hypertensive women undergoing elective cesarean section

Article

2025-09-01·NEUROPHARMACOLOGY

The biased OTR ligands -atosiban and carbetocin- differentially inhibit early or late formalin-induced nociception in rats

Article

作者: Condés-Lara, Miguel ; Martínez-Lorenzana, Guadalupe ; Guillen-Paredes, Mónica C ; González-Hernández, Abimael ; Prieto, G Aleph ; Espinosa de Los Monteros-Zúñiga, Antonio ; Almazán, Jorge Luis

Males are more sensitive to intrathecal oxytocin-induced antinociception than females. This antinociception has been linked to oxytocin receptor (OTR) activation. Canonically, OTR is coupled to Gq but can also activate Gi/o proteins. In males, the formalin test showed that oxytocin prevented early nociception (flinches) via the Gq pathway, whereas long-lasting hypersensitivity was halted by Gi/o activation. Here, we tested the effects of biased OTR ligands carbetocin (Gq) and atosiban (Gi/o) on formalin-induced nociception in male and female Wistar rats. Specifically, we assessed the effects of intrathecal carbetocin and atosiban on early (flinches) and late (paw withdrawal threshold) formalin-induced nociception. Pretreatment with L-368,899 (OTR antagonist), U-73122 (phospholipase C inhibitor), L-NAME (nitric oxide synthase inhibitor), or pertussis toxin (a Gi/o inhibitor) was used to dissect the pathways involved. Furthermore, late activation of Akt, ERK1/2, and S6 ribosomal (S6) protein was tracked in spinal tissue by immunoblotting. Carbetocin prevented early nociception in males, whereas atosiban precluded late nociception in both sexes. The antinociception induced by carbetocin and atosiban was abolished by L-368,899, pointing out the role of OTR. Pretreatment with U-73122 or L-NAME blocked the carbetocin effect, whereas pertussis toxin prevented the atosiban effect. Late hypersensitivity correlated with increased levels of phosphorylated S6 protein in the spinal tissue, an effect partly blocked by atosiban. These data suggest that carbetocin prevents early nociception in males via OTR-Gq, and atosiban blocks late hypersensitivity in both sexes via OTR-Gi/o, implying that OTR-biased activation underlies the sexual dimorphism observed in oxytocin-induced antinociception.

2025-06-26·JOURNAL OF PERINATAL MEDICINE

Comparative analysis of antidiuretic effects of oxytocin and carbetocin in postpartum hemorrhage prophylaxis: a retrospective cohort study

Article

作者: Kır, Edip Alptuğ ; Deren, Özgür ; Kayıkçı, Umutcan ; Fadıloğlu, Erdem ; Hergüner, İrem ; İskandarli, Kheyransa ; Bayrak, Ayşe Çiğdem

Abstract:

Objectives:

To compare the antidiuretic effects of oxytocin and carbetocin in patients undergoing elective caesarean section.

Methods:

This retrospective cohort study included 276 participants who underwent elective singleton caesarean sections, with 184 receiving oxytocin and 92 receiving carbetocin. Exclusion criteria comprised patients with additional medical conditions or drug use affecting urine output, those diagnosed with postpartum hemorrhage, and those requiring non-standard intravenous fluid administration or additional uterotonics. Data on demographic characteristics, urinary output, time to reach specific urine output thresholds (500 mL, 1,000 mL, and 1,500 mL), vital signs, and hemoglobin levels were collected and compared between the oxytocin and carbetocin groups.

Results:

There were no significant differences in demographic characteristics between the groups. There were no significant differences in preoperative and postoperative hemoglobin levels, vital signs or duration of hospitalization between the two groups. The carbetocin group exhibited significantly higher total urine output in the first 6 h compared to the oxytocin group (p=0.037). The time required to achieve urine output volumes of 500, 1,000, and 1,500 mL did not differ significantly between groups.

Conclusions:

Carbetocin may exert a less pronounced antidiuretic effect than oxytocin following elective caesarean section in a cohort with as few confounding factors as possible. Further prospective studies are warranted to validate these findings and assess their clinical implications in postpartum hemorrhage prophylaxis.

项与卡贝缩宫素相关的新闻（医药）

2025-06-26

·BioPharmaDive

Acadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street

Acadia Pharmaceuticals has proposed that its pipeline of experimental medicines could, if eventually brought to market, peak at $12 billion in annual sales.The brain drug developer disclosed this estimate Thursday, during its first major research and development event. The company expects eight programs to be in human testing this year, and to have data from five mid- to late-stage trials between now and the end of 2027. Five of those programs could potentially reach blockbuster status, or $1 billion or more in yearly sales, according to analysts at the investment firm Mizuho Securities.In a note to clients, Mizuho analyst Uy Ear wrote that among those programs, the majority of value comes from a drug code-named ACP-204. Researchers are currently conducting a couple mid-stage clinical trials to evaluate this drug as a possible treatment for the psychosis tied to Alzheimers disease and a related condition known as Lewy body dementia. Data from the Alzheimers study are slated to come next year.Acadia said ACP-204 is designed to build upon one of the companys two marketed products, Nuplazid, which has a similar chemical structure and was first approved in the U.S. a decade ago to treat Parkinsons disease psychosis. Nuplazid accounted for nearly two-thirds of the $958 million in revenue Acadia recorded last year. But a key patent protecting the drug from generic competition is set to expire in 2030.On Wednesday, Acadia also predicted the combined peak sales of Nuplazid and its other commercial medication, Daybue, will fall in the range of $1.5 billion to $2 billion. Approved in 2023, Daybue is used for patients with Rett syndrome, a rare, genetic disorder that impairs brain function and development.Marc Goodman, an analyst at Leerink Partners, described that forecast as very bullish. Consensus on Wall Street, according to Ear, is that sales for the two products will crest around $1.3 billion.Ear added that the wide range offered by Acadia is likely due to the recent uncertainty surrounding how many patients will stop taking Daybue because of its side effects. The drugs label includes warnings for diarrhea and weight loss.Along with ACP-204, Acadias pipeline includes ACP-101, a drug for another rare, genetic, neurological disease called Prader-Willi Syndrome. High-level results from a Phase 3 experiment should arrive sometime between October and December. Theres also ACP-211, for major depression; ACP-711, for essential tremor; and ACP-2591, a next-generation approach to addressing Rett syndrome. Each of those three programs are in early-stage testing.Forecasting Acadia's pipeline potentialDrugStageIndicationPeak sales potentialACP-101Ph. 3Prader-Willi Syndrome~$1-2BACP-204Ph. 2Alzheimers psychosis, Lewy body dementia psychosis>$2BACP-211Ph. 2Major depressive disorder>$2BACP-271Ph. 1-readyHuntingtons disease, tardive dyskinesia~$1-2BACP-711Ph. 2Essential tremor>$2BSOURCE: Table and estimates from research by Mizuho Securities analyst Uy Ear.Additionally, Acadia has a preclinical therapy, ACP-271, that it plans to test in patients with Huntingtons disease or tardive dyskinesia, a condition hallmarked by uncontrolled movements and a side effect that can arise from the long-term use of some brain-stabilizing medications like antipsychotics.Analysts reacted well to Acadias updates. Ear left the R&D presentation encouraged, while Goodman wrote how his team is now incrementally more positive on the company. Acadias stock price has been weighed down over much of the last five years, as the company hit setbacks trying to expand the use of Nuplazid into more lucrative markets.In his note, Goodman acknowledged that investors will probably have a show me the data attitude regarding these new assets as well as a healthy skepticism around the potential of both ACP-204 and ACP-101. So it may take some time for pipeline value to creep into the companys valuation.Should Nuplazid and Daybue ultimately achieve Acadias new forecast, that would make the companys stock attractive even if the experimental programs dont pan out, Goodman wrote.However, the real upside is that Acadia hits on an asset or two to make the name a sustainable growth story, he added. We are certainly willing to be patient to see this story play out.Acadia shares traded around $22.60 apiece late Thursday morning, essentially flat from the prior days close. '

上市批准临床3期

2025-06-04

·赛柏蓝

58同城，控股了一家知名药企

作者 | 陈芋苒苒责编 | 遥望单一产品营收贡献超七成，新实控人跨界入局能否撬动老牌药企第二增长曲线？01上市药企易主，管理层“换血”对赌承诺三年营收、净利6月3日晚间，易明医药发布公告，其控股股东、实际控制人高帆与北京福好企业管理合伙企业签署《股份转让协议》，北京福好拟协议收购高帆持有的23%公司股份，转让价格为15.1元/股，总转让价款为6.62亿元。本次权益变动实施完成后，易明医药控股股东将由高帆变更为北京福好，实际控制人将由高帆变更为姚劲波。姚劲波最广为人知的身份是“58同城”创始人，曾在2013年带领58同城实现IPO，后完成系列资本运作，正式成立58集团。6月4日，易明医药复牌即封涨停，截至收盘，易明医药股价报收于13.40元，总市值25.55亿。北京福好受让股份后，易明医药管理层也将“换血”——北京福好将向易明医药推荐3名非独立董事及3名独立董事，高帆将推荐1名非独立董事；易明医药财务总监、董事会秘书将由北京福好提名。易明医药的2名关键人员将继续留任，负责经营现有业务板块，其中1位关键人员可给予集团公司副总裁级别职务。除上述人员外，高帆委派或提名的其他高级管理人员将根据北京福好的需求相应辞去职务。双方还就转让后的营收与净利润立下了对赌协议。协议显示，转让方承诺易明医药2025年-2027年归母净利润均不低于3000万元；如易明医药现有业务板块期间任一年度内出现未能实现承诺净利润的情形，转让方应以现金对受让方进行补偿（现金补偿款金额=该年度承诺利润-现有业务板块在该年度实际实现的经审计的扣非归母净利润）。对于营收，转让方承诺易明医药在2025年-2027年中每个会计年度内实现的营收不低于6亿元，如达到承诺营收的90%，即5.4亿元，转让方无需向受让方进行补偿；若低于承诺营收的90%，则转让方应向受让方作适当补偿，具体安排由双方另行协商。参考易明医药近5年业绩情况，除2023年归母净利润不足3000万元以外，其余年份的营收及净利均超过此次协议中的承诺金额。不过，自2023年起，易明医药营收持续下滑，今年第一季度，易明医药实现营业收入1.49亿元，同比下降7.41%。02新实控人跨界入局能否撬动第二增长曲线？姚劲波此前对医药行业涉猎不多，不过，作为中国初代互联网巨头，其创立的58同城曾是股权投资市场最活跃的投资方之一。工商信息显示，58同城的公开投资事件近百起，2013年后尤为密集。2013年，58同城顺利登陆纽交所，并在上市当天收盘暴涨42%。此后，58同城通过投资、收并购不断拓展业务版图，覆盖房产家居、汽车服务、生活服务、人才招聘等领域，安居客、我爱我家、赶集网、啄木鸟、快狗打车、转转、驾校一点通、中华英才网等都是其当时“出手”的对象。姚劲波甚至公开表示，要投资100家O2O公司，以持续扩张来形成58的生态体系。但随着互联网从PC端向移动端迁移，58同城不断扩大的业务并未如愿形成健康的生态体系，2015年-2020年，58同城营收增速持续下滑，从185.1%的增速跌落到-15.45%。2020年9月，58同城宣告从纽交所退市，姚劲波联合华平投资、鸥翎投资等以87亿美元对企业进行了私有化。此后，58同城在投资与收并购方面也放慢了脚步。此次跨界入局医药，或是姚劲波的“下一盘棋”——切入壁垒更高、成长性更好的医药健康赛道，调整资本版图。易明医药创立于2003年，2016年在深圳证券交易所中小板正式挂牌上市，产品覆盖糖尿病、心血管疾病等老年慢性病治疗药物及妇科产科领域，包括米格列醇片、瓜蒌皮注射液、卡贝缩宫素注射液等。其中，米格列醇片是最核心的产品。作为国内首仿药，易明医药的米格列醇片在我国米格列醇制剂市场中份额连年稳居首位。2021年，其米格列醇片在第五批国采中中标。2024年，米格列醇片实现营收4.74亿元，占易明医药总营收的70%以上。在今年5月中旬召开的业绩说明会上，有投资者表达了对易明医药过于依赖单一产品的担忧。易明医药回复称，其将挖掘现有批件品种的临床价值，择时启动部分休眠产品的生产营销规划；持续发掘在品质及临床中有医学价值和商业价值，在细分行业里有特色的产品，采取购买生产批件、药品上市许可持有人资格、经营权、引进国外已上市产品和技术等形式，完善产品体系。据分析，姚劲波在互联网行业积累了丰富的资源整合与运营经验，可能会推动易明医药从传统医药企业向综合医药健康企业的转型，例如拓展医药电商、医疗服务等新兴领域。“58系”庞大的线上流量入口和本地生活服务网络，若能将这些资源与易明医药的慢病管理产品结合，或可创造“互联网+慢病管理”新模式。在创业和投资圈，德州扑克是最为风靡的游戏之一。“很多人相信可以用德州来识人”，有业内人士曾在文章中写道，“58同城创始人姚劲波，入局率65%，摊牌率居然高达60%，入局率和摊牌率的比例惊人地高，说明他一旦入局就不会放弃——这种对手太可怕了。”随着实控人更迭，易明医药或将迎来战略重塑。未来，易明医药将与新实控人共同创造第二增长曲线，还是仍难摆脱单品依赖？双方的下一步棋都值得持续观察。（更多前情信息可见：《知名药企将易主！创始人或「退场」》）END内容沟通：郑瑶（13810174402）

并购高管变更IPO财报

2025-06-02

·信狐药迅

国产五个1类新药，其中优先品种加思科KRAS 抑制剂格来雷塞肺癌适应症获批上市| 新获批(5.26-6.1）

每周药品注册获批数据，分门别类呈现，一目了然。(5.26-6.1）新药上市申请药品名称企业注册分类受理号枸橼酸格来雷塞片北京加科思新药研发有限公司1CXHS2400044昂拉地韦片广东众生睿创生物科技有限公司1CXHS2300118沙库巴曲阿利沙坦钙片深圳信立泰药业股份有限公司1CXHS2300060沙库巴曲阿利沙坦钙片深圳信立泰药业股份有限公司1CXHS2300059瑞格列汀二甲双胍片(II)山东盛迪医药有限公司1CXHS2300012瑞格列汀二甲双胍片(I)山东盛迪医药有限公司1CXHS2300011昂戈瑞西单抗注射液上海君实生物医药科技股份有限公司1CXSS2400031昂戈瑞西单抗注射液上海君实生物医药科技股份有限公司1CXSS2400030昂戈瑞西单抗注射液上海君实生物医药科技股份有限公司1CXSS2400029昂戈瑞西单抗注射液上海君实生物医药科技股份有限公司1CXSS2400028注射用泰它西普荣昌生物制药(烟台)股份有限公司2.2CXSS2400115新药临床申请药品名称企业注册分类受理号WSD0922-FU片杭州威瑞宝生物医药有限公司1CXHL2500322WSD0922-FU 片杭州威瑞宝生物医药有限公司1CXHL2500321Alpha-0261片深圳阿尔法分子科技有限责任公司1CXHL2500316Alpha-0261片深圳阿尔法分子科技有限责任公司1CXHL2500315ICP-248片北京诺诚健华医药科技有限公司1CXHL2500308ICP-248片北京诺诚健华医药科技有限公司1CXHL2500307RFUS-949片宜昌人福药业有限责任公司1CXHL2500297RFUS-949片宜昌人福药业有限责任公司1CXHL2500296苹果酸法米替尼胶囊江苏恒瑞医药股份有限公司1CXHL2500298塞拉维诺片中国科学院上海药物研究所1CXHL2500291塞拉维诺片中国科学院上海药物研究所1CXHL2500290ZYS-1肠溶片北京科佑爱科技有限责任公司1CXHL2500286PLB1004胶囊鞍石药业(宁波)有限责任公司1CXHL2500284PLB1004胶囊鞍石药业(宁波)有限责任公司1CXHL2500283HMPL-306片和记黄埔医药(上海)有限公司1CXHL2500282HMPL-306片和记黄埔医药(上海)有限公司1CXHL2500281注射用KH617四川弘合生物科技有限公司1CXHL2500274GFH312 片劲方医药科技(上海)股份有限公司1CXHL2500273LT-002-158片领泰生物医药(绍兴)有限公司1CXHL2500272LT-002-158片领泰生物医药(绍兴)有限公司1CXHL2500271MWX203注射液上海民为生物技术有限公司1CXHL2500270RGT-274-CR胶囊上海齐鲁锐格医药研发有限公司1CXHL2500268RGT-274-CR胶囊上海齐鲁锐格医药研发有限公司1CXHL2500267RGT-274-CR胶囊上海齐鲁锐格医药研发有限公司1CXHL2500266HRS9531注射液福建盛迪医药有限公司1CXHL2500260HRS9531注射液福建盛迪医药有限公司1CXHL2500259奎斯诺片中科南京生命健康高等研究院1CXHL2500245注射用Neu-001神瞻医药(深圳)有限公司1CXHL2500232布瑞哌唑口溶膜上海现代制药股份有限公司2.2CXHL2500310布瑞哌唑口溶膜上海现代制药股份有限公司2.2CXHL2500309PDX-04湖南九典制药股份有限公司2.2CXHL2500289PDX-04湖南九典制药股份有限公司2.2CXHL2500288布瑞哌唑口溶膜江西远超医药科技有限公司2.2CXHL2500280布瑞哌唑口溶膜江西远超医药科技有限公司2.2CXHL2500279MDN-001注射液苏州迈得诺意医疗技术有限公司2.2CXHL2500269BCM995上海云晟研新生物科技有限公司2.2CXHL2500221SMF-217江西施美药业股份有限公司2.3CXHL25002336价B族链球菌结合疫苗苏州聚微生物科技有限公司1.1CXSL2500190呼吸道合胞病毒mRNA疫苗艾美创新者生物医药研究(上海)有限公司1.2CXSL2500181ACYW135X群脑膜炎球菌多糖结合疫苗北京科兴中维生物技术有限公司1.4CXSL250020024价肺炎球菌结合疫苗苏州聚微生物科技有限公司1.4CXSL2500183冻干二价重组呼吸道合胞病毒疫苗(CHO细胞)广州穗和生物技术有限公司1.4CXSL2500180注射用TQB2102正大天晴药业集团南京顺欣制药有限公司1CXSL2500241BT02单克隆抗体注射液上海柏全生物科技有限公司1CXSL2500236GB18注射液深圳科兴药业有限公司1CXSL2500226SSS55注射液沈阳三生制药有限责任公司1CXSL2500235IBI363信达生物制药(苏州)有限公司1CXSL2500233IBI363信达生物制药(苏州)有限公司1CXSL2500232注射用SHR-A1811苏州盛迪亚生物医药有限公司1CXSL2500230注射用AK146D1中山康方生物医药有限公司1CXSL2500227GLS-W1100胶囊杭州远大生物制药有限公司1CXSL2500224SPGL008注射液深圳赛保尔生物药业有限公司1CXSL2500223EMB-01注射液上海岸迈生物科技有限公司1CXSL2500222REGEND003细胞自体回输制剂上海吉锐医学科技有限公司1CXSL2500196NTB003注射液南京正大天晴制药有限公司1CXSL2500197人脐带间充质干细胞注射液北京拓华伟业生物科技有限公司1CXSL2500187注射用MK-2870默沙东研发(中国)有限公司2.2CXSL2500244阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500231仿制药申请药品名称企业注册分类受理号富马酸酮替芬口服溶液武汉贝参药业股份有限公司3CYHS2402516乙酰半胱氨酸注射液江苏宝东医药科技有限公司3CYHS2402010药用炭胶囊海南烨徽源医药科技有限公司3CYHS2401658酒石酸美托洛尔注射液华夏生生药业(北京)有限公司3CYHS2303566吸入用盐酸氨溴索溶液合肥国药诺和药业有限公司3CYHS2303288盐酸苯海拉明片长春海悦药业股份有限公司3CYHS2303105吡拉西坦注射液山东化药医药科技有限公司3CYHS2303050吡拉西坦注射液山东化药医药科技有限公司3CYHS2303049吡拉西坦注射液山东化药医药科技有限公司3CYHS2303048甘油果糖氯化钠注射液湖北美林药业有限公司3CYHS2302989腺苷钴胺胶囊湖北凯安晨医药科技有限公司3CYHS2302907托伐普坦口腔崩解片南京海纳制药有限公司3CYHS2302886托伐普坦口腔崩解片南京海纳制药有限公司3CYHS2302885托拉塞米注射液江苏天士力帝益药业有限公司3CYHS2302873托拉塞米注射液江苏天士力帝益药业有限公司3CYHS2302872氨氯地平贝那普利胶囊广东粤和泽药物研究有限公司3CYHS2302835氟[18F]化钠注射液南京江原安迪科正电子研究发展有限公司3CYHS2302776盐酸普萘洛尔注射液南京泽恒医药技术开发有限公司3CYHS2302310重酒石酸去甲肾上腺素注射液江苏江丰医药科技有限公司3CYHS2302293盐酸拉贝洛尔注射液南京恒道医药科技股份有限公司3CYHS2302193甲硫酸新斯的明注射液宝利化(南京)制药有限公司3CYHS2301869琥珀酸舒马普坦萘普生钠片康缘华威医药有限公司3CYHS2301119盐酸肾上腺素注射液上海葆隆生物科技有限公司3CYHS2301110布洛芬注射液山东罗欣药业集团股份有限公司3CYHS2201969国;CYHS2201969氧(液态)贵州省黔东南州炉园气体有限公司4CYHS2402303非诺贝特酸胆碱缓释胶囊江苏万高药业股份有限公司4CYHS2401152非诺贝特酸胆碱缓释胶囊江苏万高药业股份有限公司4CYHS2401151卡贝缩宫素注射液长春圣金诺生物制药有限公司4CYHS2401031来特莫韦片重庆希韦医药科技有限公司4CYHS2400949注射用氯诺昔康海南卫康制药(潜山)有限公司4CYHS2400902乙酰半胱氨酸颗粒湘北威尔曼制药股份有限公司4CYHS2400660乙酰半胱氨酸颗粒湘北威尔曼制药股份有限公司4CYHS2400659苯磺顺阿曲库铵注射液吉林天成制药有限公司4CYHS2400583苯磺顺阿曲库铵注射液吉林天成制药有限公司4CYHS2400584达格列净片山东新时代药业有限公司4CYHS2400514他克莫司软膏中山万汉制药有限公司4CYHS2400507他克莫司软膏中山万汉制药有限公司4CYHS2400506阿仑膦酸钠片安徽艾立德制药有限公司4CYHS2400444缬沙坦氨氯地平片(II)浙江众延医药科技有限公司4CYHS2400175盐酸普拉克索片植恩生物技术股份有限公司4CYHS2400101盐酸普拉克索片植恩生物技术股份有限公司4CYHS2400102左氧氟沙星氯化钠注射液海南爱科制药有限公司4CYHS2303643左氧氟沙星氯化钠注射液海南爱科制药有限公司4CYHS2303642沙格列汀二甲双胍缓释片南京易亨制药有限公司4CYHS2303476注射用阿奇霉素海南斯达制药有限公司4CYHS2303439黄体酮软胶囊武汉九珑人福药业有限责任公司4CYHS2303375黄体酮软胶囊武汉九珑人福药业有限责任公司4CYHS2303374艾地骨化醇软胶囊广州江正医药科技有限公司4CYHS2303159艾地骨化醇软胶囊广州江正医药科技有限公司4CYHS2303158富马酸伏诺拉生片浙江核力欣健药业有限公司4CYHS2302997富马酸伏诺拉生片浙江核力欣健药业有限公司4CYHS2302999醋酸阿托西班注射液安徽安科生物工程(集团)股份有限公司4CYHS2302814醋酸阿托西班注射液安徽安科生物工程(集团)股份有限公司4CYHS2302813达可替尼片成都苑东生物制药股份有限公司4CYHS2300479达可替尼片成都苑东生物制药股份有限公司4CYHS2300478甲苯磺酸索拉非尼广州白云山医药集团股份有限公司白云山化学制药厂CYHS2360970抗A抗B血型定型试剂(单抗)长春博迅生物技术有限责任公司CXSS2400097米诺地尔泡沫剂深圳珐玛易药品科技有限公司3CYHL2500066艾拉戈克钠片东莞松山湖美健生物技术有限公司3CYHL2500063艾拉戈克钠片东莞松山湖美健生物技术有限公司3CYHL2500062注射用醋酸亮丙瑞林混悬液苏州善湾生物医药科技有限公司3CYHL2500060利多卡因丙胺卡因气雾剂福元药业有限公司3CYHL2500059奥泽沙星洗剂杭州中美华东制药有限公司3CYHL2500058咪达唑仑鼻喷雾剂四川普锐特药业有限公司3CYHL2500057厄贝沙坦氨氯地平片杭州沐源生物医药科技有限公司3CYHL2500056盐酸毛果芸香碱滴眼液鲁南贝特制药有限公司3CYHL2500052贝美前列素涂剂海南斯达制药有限公司3CYHL2500051硝呋太尔制霉菌素阴道软胶囊山东华铂凯盛生物科技有限公司4CYHL2500069异丙托溴铵吸入气雾剂山东达因海洋生物制药股份有限公司4CYHL2500061进口申请药品名称企业注册分类受理号莱博雷生片Eisai Co., Ltd.5.1JXHS2400006莱博雷生片Eisai Co., Ltd.5.1JXHS2400005Clesrovimab注射液Merck Sharp & Dohme B.V.1JXSS2500042Golcadomide胶囊Celgene Corporation1JXHL2500055Golcadomide胶囊Celgene Corporation1JXHL2500054Golcadomide胶囊Celgene Corporation1JXHL2500053Golcadomide胶囊Celgene Corporation1JXHL2500052MK-1084片Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2500051MK-1084片Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2500050[225Ac]Ac-PSMA-617注射液Novartis Pharma AG1JXHL2500047VSA001注射液Arrowhead Pharmaceuticals, Inc.1JXHL2500045TQJ230注射液Novartis Pharma AG1JXHL2500044ELVN-001胶囊Enliven Therapeutics, Inc.1JXHL2500043SAR441566Sanofi-Aventis Recherche & Développement1JXHL2500042LY3549492片Eli Lilly and Company1JXHL2500041LY3549492片Eli Lilly and Company1JXHL2500040LY3549492片Eli Lilly and Company1JXHL2500039LY3549492片Eli Lilly and Company1JXHL2500038地非法林注射液Vifor Fresenius Medical Care Renal Pharma Ltd.2.4JXHL2500049用于制备放射性药物镓(68Ga)gozetotide注射液的药盒Novartis Europharm Limited5.1JXHL2500046帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2500043中药相关申请药品名称企业注册分类受理号小儿热立清颗粒奇正(珠海市横琴)国际医药有限公司1.1CXZL2500015银苓通脉健脑颗粒海南鑫康达医药科技有限公司1.1CXZL2500014清喉咽含片浙江康恩贝制药股份有限公司2.1CXZS2300018注：橙色字体部分结论为不批准或收到通知件；

上市批准申请上市

100 项与卡贝缩宫素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07229	卡贝缩宫素	H01BB03	DB01282

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
出血	澳大利亚	Ferring Pharmaceuticals Pty Ltd.	2015-04-17
宫缩乏力	澳大利亚	Ferring Pharmaceuticals Pty Ltd.	2015-04-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多食症	临床3期	美国	ACADIA Pharmaceuticals, Inc.	2023-11-27
多食症	临床3期	加拿大	ACADIA Pharmaceuticals, Inc.	2023-11-27
多食症	临床3期	法国	ACADIA Pharmaceuticals, Inc.	2023-11-27
多食症	临床3期	德国	ACADIA Pharmaceuticals, Inc.	2023-11-27
多食症	临床3期	西班牙	ACADIA Pharmaceuticals, Inc.	2023-11-27
多食症	临床3期	英国	ACADIA Pharmaceuticals, Inc.	2023-11-27
普拉德-威利综合症	临床3期	澳大利亚	Levo Therapeutics, Inc.	2018-11-20
产后出血	临床3期	英国	Ferring Pharmaceuticals A/S	2015-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01968187 (CTgov)	临床2期	多食症 \| 普拉德-威利综合症	38	FE 992097 (Carbetocin (FE 992097))	鬱網鹽窪憲網網鏇襯構(獵繭築遞餘鏇衊齋夢網) = 壓鹹憲鏇鏇糧積鏇餘鏇蓋壓簾製壓鹹鹽網齋積 (繭獵鏇鹹壓衊夢膚鑰積, 3.06) 更多	-	2025-03-27
				Placebo (Placebo)	鬱網鹽窪憲網網鏇襯構(獵繭築遞餘鏇衊齋夢網) = 鹽糧夢艱憲醖膚願鏇積蓋壓簾製壓鹹鹽網齋積 (繭獵鏇鹹壓衊夢膚鑰積, 2.61) 更多
NCT03899961 (CMT2014/2, CTgov)	临床4期	妊娠并发症	240	Oxytocin (Oxytocin)	獵膚膚憲鏇築衊夢襯構(窪觸淵獵餘網構醖餘蓋) = 顧觸觸齋獵蓋構鏇觸醖廠鹽糧醖壓積夢糧醖範 (網構積衊鬱憲網鏇艱糧, 鏇憲顧簾衊艱繭鬱壓積 ~ 壓鹽鹹鹽網鏇築獵蓋鏇) 更多	-	2025-03-25
				Carbetocin (Carbetocin)	獵膚膚憲鏇築衊夢襯構(窪觸淵獵餘網構醖餘蓋) = 積遞鏇積選膚壓鏇夢壓廠鹽糧醖壓積夢糧醖範 (網構積衊鬱憲網鏇艱糧, 艱構範製鏇鹽鑰蓋獵製 ~ 衊膚艱構艱艱繭廠築築) 更多
NCT03649477 (CARE-PWS, CTgov)	临床3期	普拉德-威利综合症	130	9.6 mg intranasal carbetocin (9.6 mg of LV-101)	窪淵衊積夢鏇廠製廠襯(齋壓糧淵範餘艱鹽繭憲) = 夢獵窪簾鹽觸壓窪觸夢獵衊鬱網憲網壓繭衊鹹 (鏇鏇鹹夢構糧簾膚選鹽, 廠顧構鹹餘觸鹽廠醖觸 ~ 構糧構觸簾繭憲夢衊鏇) 更多	-	2021-11-17
				3.2 mg intranasal carbetocin (3.2 mg of LV-101)	窪淵衊積夢鏇廠製廠襯(齋壓糧淵範餘艱鹽繭憲) = 製遞網衊範襯糧獵鹹餘獵衊鬱網憲網壓繭衊鹹 (鏇鏇鹹夢構糧簾膚選鹽, 夢壓廠淵簾醖願構範鹽 ~ 願醖範壓鹹廠膚構築鬱) 更多
NCT03716076 (CaRDIO, CTgov)	临床4期	窦性心律失常	50	Carbetocin (Participant Receives 50 mcg of Carbetocin Post-delivery.)	簾鬱醖壓願顧鏇鏇積廠(糧鹹窪餘廠鹽積鏇糧餘) = 鬱築構顧構範餘糧顧艱鏇築顧製蓋淵衊鹹選鏇 (範鹹範選鏇簾餘鬱夢鹽, 7.7) 更多	-	2021-05-14
				Carbetocin (Participant Receives 100 mcg of Carbetocin Post-delivery.)	簾鬱醖壓願顧鏇鏇積廠(糧鹹窪餘廠鹽積鏇糧餘) = 壓廠鹹願鏇鏇鏇齋積齋鏇築顧製蓋淵衊鹹選鏇 (範鹹範選鏇簾餘鬱夢鹽, 4.7) 更多
NCT03649477 (CARE-PWS, ENDO2021)	临床3期	普拉德-威利综合症 hypothalamic oxytocin levels	119	Carbetocin 3.2 mg	繭願鹽網廠觸繭鹽憲網(窪遞製鑰鬱餘鹽觸壓夢) = Numeric trends toward improvement in CY-BOCS scores were observed in each dose arm, but did not reach statistical significance versus placebo 壓製鏇構憲顧範醖選觸 (鏇簾鏇齋窪積醖構鑰觸 ) 更多	积极	2021-05-03
NCT03649477 (CARE-PWS, BusinessWire) 人工标引	临床3期	普拉德-威利综合症	119	LV-101	餘壓遞顧糧願衊鬱餘餘(顧積遞選膚鬱餘餘鑰簾) = not meet 觸膚窪艱顧構廠遞鹹蓋 (壓築衊衊願範鹽顧觸觸 ) 更多	积极	2020-08-06
				Placebo
NCT03716076 (Pubmed \| Anesth Analg)	临床4期	-	50	Carbetocin 50 µg	鑰糧壓鹹觸構鬱觸膚膚(網網遞積範鬱製網積鬱): milliseconds = 4.1 (95% CI, 0.8 ~ 7.5)	-	2020-03-05
				Carbetocin 100 µg
NCT03672045 (Pubmed \| Anaesthesia)	N/A	肥胖	30	Carbetocin	選觸鏇顧顧築膚繭憲齋(糧夢構壓製憲構遞觸蓋) = 顧膚鏇膚觸觸憲鑰繭顧築鏇願範膚築鏇鹽衊積 (鹹壓築齋醖觸襯衊鏇築, 621 ~ 1178) 更多	-	2020-03-01
ACTRN12614000870651 (CHAMPION, Pubmed \| N Engl J Med)	临床3期	产后出血	-	Heat-stable carbetocin	淵獵壓顧築壓構鏇窪鏇(糧繭膚鬱艱糧艱醖網夢) = 願製鑰齋膚鏇製廠淵夢鹹廠糧選願構觸鏇鏇網 (窪願積糧廠網積鏇鏇艱 )	-	2018-08-23
				Oxytocin	淵獵壓顧築壓構鏇窪鏇(糧繭膚鬱艱糧艱醖網夢) = 窪鬱窪齋鹽廠淵衊餘糧鹹廠糧選願構觸鏇鏇網 (窪願積糧廠網積鏇鏇艱 )
TCTR20160715004 (Pubmed \| Arch Gynecol Obstet)	N/A	怀孕	-	Intravenous carbetocin	蓋製窪淵鑰鑰鏇遞顧夢(製糧願餘襯糧壓醖艱鏇) = 廠艱獵憲醖壓構壓襯獵構顧鹽鑰窪鏇繭醖衊繭 (憲構簾構壓鏇繭築築網 ) 更多	积极	2018-08-01
				Intravenous oxytocin	憲窪簾齋憲範襯窪衊糧(齋醖簾糧艱鏇艱範顧壓) = 憲積網鬱鏇夢憲選蓋製繭遞積壓鬱衊顧淵夢積 (衊願構鏇齋觸觸範壓衊 ) 更多